Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer-Reference-Cited by-同舟云学术

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer

Published:2022-10 Issue: Volume:32 Page:100826
ISSN:1476-5586
Container-title:Neoplasia
language:en
Short-container-title:Neoplasia

Author:

Oosterwijk-Wakka Jeannette C.^ORCID,de Weijert Mirjam C.A.,Franssen Gerben M.,Kolev Dimitar R.,de Haan Ton A.F.J.,Boerman Otto C.,Mulders Peter F.A.,Oosterwijk Egbert

Funder

Seventh Framework Programme

Publisher

Elsevier BV

Subject

Cancer Research

Reference33 articles.

1. Systemic treatment of renal cell cancer: a comprehensive review;Sanchez-Gastaldo;Cancer Treat Rev,2017

2. Treatment of renal cell carcinoma: current status and future directions;Barata;CA Cancer J Clin,2017

3. Immunotherapy: a new standard in the treatment of metastatic clear cell renal cell carcinoma;Popovic;World J Clin Oncol,2022

4. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

5. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial;Bracarda;BJU Int,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology;The Lancet Oncology;2024-06

2. Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents;Cell Communication and Signaling;2024-04-15